GO:0005894 interleukin-3 receptor complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005894 (interleukin-3 receptor complex) is a cell-surface protein complex that binds interleukin-3 (IL-3) and consists of a ligand-specific alpha subunit (IL3RA/CD123) and a shared beta subunit (CSF2RB/CD131).
• The beta subunit is shared with the receptors for GM-CSF and IL-5, forming the common beta (CD131) signaling module that defines a family of cytokine receptors.
• IL-3 receptor signaling supports survival, proliferation, and differentiation of hematopoietic progenitor cells, making it central to hematopoiesis research.
• The alpha subunit CD123 is overexpressed in several hematological malignancies, including acute myeloid leukemia, and is an active target for antibody and cell-based therapies.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of IL3RA and CSF2RB contributions to receptor assembly and signaling.
• Understanding the interleukin-3 receptor complex informs drug design, immunotherapy safety, and the biology of inflammatory and myeloproliferative diseases.
Description
The interleukin-3 receptor complex (GO:0005894) is a heteromeric cell-surface protein complex that specifically binds the cytokine interleukin-3 (IL-3) and initiates intracellular signaling. According to the Gene Ontology, this complex comprises an alpha subunit, which is unique to the IL-3 receptor, and a beta subunit that is shared with the receptors for granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-5 (IL-5). This shared beta chain, often termed CD131 or common beta, is a defining feature of a small cytokine receptor family and explains why IL-3, GM-CSF, and IL-5 can trigger overlapping but distinct cellular responses. Researchers study the interleukin-3 receptor complex because it is a key regulator of hematopoietic cell survival, proliferation, and differentiation. IL-3 signaling supports the expansion of myeloid progenitors and is critical for the response to infection and inflammation. Dysregulation of this receptor complex has been linked to hematological malignancies, particularly acute myeloid leukemia (AML), where the alpha subunit CD123 is frequently overexpressed and is being pursued as a therapeutic target. From a methodological standpoint, the interleukin-3 receptor complex serves as a model for understanding cytokine receptor assembly, shared signaling subunits, and the structural basis of ligand discrimination. Recent structural and antibody-based studies have revealed how the receptor can be blocked and how signaling is organized, providing a template for therapeutic intervention. This article summarizes the current knowledge of the complex, its components, its regulation, and the experimental strategies used to study it.
interleukin-3 receptor complex At A Glance
| GO ID | GO:0005894 |
|---|---|
| GO term | interleukin-3 receptor complex |
| Ontology | cellular_component |
| Synonym | IL-3 receptor complex |
| Definition | A protein complex that binds interleukin-3; comprises an alpha and a beta subunit. The alpha chain is specific to the interleukin-3 receptor, whereas the beta chain is shared with the receptors for granulocyte-macrophage colony-stimulating factor and interleukin-5. |
| Major function | Binds IL-3 and initiates signaling that promotes survival, proliferation, and differentiation of hematopoietic cells. |
| Subunits | Alpha subunit (IL3RA/CD123) and beta subunit (CSF2RB/CD131). |
| Shared beta chain | The beta subunit is shared with GM-CSF and IL-5 receptors. |
| Disease relevance | CD123 overexpression in AML and other hematological malignancies; target for immunotherapy. |
What Is GO:0005894?
The interleukin-3 receptor complex (GO:0005894) is a protein complex located at the cell surface that binds interleukin-3. It is composed of two distinct subunits: an alpha chain (IL3RA/CD123) that is specific to the IL-3 receptor, and a beta chain (CSF2RB/CD131) that is shared with the receptors for GM-CSF and IL-5. This shared beta subunit is responsible for signal transduction, while the alpha subunit confers ligand specificity.
Why Is interleukin-3 receptor complex Important in Cell Biology?
The interleukin-3 receptor complex is essential for normal hematopoiesis and immune responses, and its dysregulation contributes to leukemia and inflammatory diseases. Because the beta subunit is shared with GM-CSF and IL-5 receptors, studying this complex provides insight into cytokine receptor cross-talk and the design of targeted therapies that can selectively modulate one or more of these pathways. The alpha subunit CD123 is a clinically validated target in AML, and understanding the complex at the structural and functional level is critical for developing safe and effective immunotherapies.
• Regulates survival and proliferation of hematopoietic progenitor cells.
• Central to myeloid differentiation and immune cell production.
• Shared beta subunit explains overlapping functions of IL-3, GM-CSF, and IL-5.
• CD123 (IL3RA) is overexpressed in AML and other malignancies, making it a therapeutic target.
• Involved in inflammatory responses and potentially in gout-related innate immunity.
• Provides a model for understanding cytokine receptor assembly and signaling.
• Enables development of blocking antibodies and targeted immunotherapies.
• Supports research on bone marrow failure, myeloproliferative disorders, and immune deficiencies.
Core Biology of the interleukin-3 receptor complex
Ligand Binding and Receptor Activation
In simple terms: IL-3 binds to the alpha subunit, which then recruits the shared beta subunit to trigger signaling.
The interleukin-3 receptor complex is activated when IL-3 binds to the alpha subunit (IL3RA/CD123) with high affinity. This binding induces a conformational change that allows the alpha subunit to recruit the shared beta subunit (CSF2RB/CD131), forming a functional signaling complex. The beta subunit is shared with GM-CSF and IL-5 receptors, and its engagement is the key step for signal transduction. Structural studies of the related IL-5 receptor complex have revealed an organizing principle for common beta cytokine signaling, which likely applies to the IL-3 receptor complex.
Signal Transduction Pathways
In simple terms: Once assembled, the receptor activates intracellular pathways that tell the cell to survive and grow.
Upon assembly, the beta subunit activates associated Janus kinases (JAKs), leading to phosphorylation of downstream targets such as STAT5, PI3K/AKT, and MAPK pathways. These signals promote cell survival, proliferation, and differentiation of hematopoietic cells. The specific outcomes depend on the cell context and the availability of other cytokines, but the core signaling machinery is shared among IL-3, GM-CSF, and IL-5 receptors.
Biological Outcomes in Hematopoiesis
In simple terms: The receptor helps produce and maintain blood cells, especially myeloid cells.
IL-3 receptor signaling is critical for the expansion and maintenance of hematopoietic progenitor cells, particularly those of the myeloid lineage. It supports the survival of these progenitors and their differentiation into granulocytes, monocytes, and other cell types. In vivo, IL-3 acts synergistically with other cytokines to regulate steady-state hematopoiesis and stress responses.
Structural Organization of the Receptor Complex
In simple terms: The receptor is made of two different protein chains that fit together like a lock and key.
The interleukin-3 receptor complex is a heterodimer composed of an alpha subunit (IL3RA/CD123) and a beta subunit (CSF2RB/CD131). The alpha subunit contains a cytokine-binding domain that confers specificity for IL-3, while the beta subunit contains the signaling motifs. The beta subunit is shared with GM-CSF and IL-5 receptors, and its structure is characterized by a conserved extracellular domain and intracellular regions that bind JAK kinases. Recent cryo-EM structures of the related IL-5 receptor complex have provided a framework for understanding how these shared subunits assemble.
Regulation of Receptor Expression and Activity
In simple terms: Cells control how much receptor they make and how sensitive they are to IL-3.
Expression of the alpha subunit (IL3RA/CD123) is regulated in a cell-type-specific manner, with high levels in plasmacytoid dendritic cells and some myeloid progenitors. The beta subunit (CSF2RB/CD131) is more broadly expressed. Receptor activity can be modulated by ligand availability, receptor internalization, and negative feedback loops involving SOCS proteins and phosphatases. In disease states, such as AML, CD123 expression is often elevated, contributing to enhanced IL-3 responsiveness.
Key Genes Involved in GO:0005894 interleukin-3 receptor complex
The following genes encode the subunits of the interleukin-3 receptor complex and related signaling molecules that are commonly studied in this context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL3RA | Encodes the alpha subunit (CD123) specific for IL-3 binding | Target for AML therapy; marker of plasmacytoid dendritic cells |
| CSF2RB | Encodes the shared beta subunit (CD131) that transduces signals | Common subunit for IL-3, GM-CSF, and IL-5 receptors |
| JAK2 | Janus kinase that associates with the beta subunit and initiates signaling | Mutations in JAK2 are linked to myeloproliferative neoplasms |
| STAT5A | Transcription factor activated downstream of JAK2 | Mediates survival and proliferation signals |
| STAT5B | Transcription factor activated downstream of JAK2 | Mediates survival and proliferation signals |
| PIK3CA | Catalytic subunit of PI3K, involved in AKT activation | Promotes cell survival and growth |
| AKT1 | Serine/threonine kinase downstream of PI3K | Key survival signaling node |
| MAPK1 | Extracellular signal-regulated kinase 2 (ERK2) | Proliferation signaling |
| MAPK3 | Extracellular signal-regulated kinase 1 (ERK1) | Proliferation signaling |
| SOCS1 | Suppressor of cytokine signaling, negative feedback | Regulates receptor signaling duration |
| SOCS3 | Suppressor of cytokine signaling, negative feedback | Regulates receptor signaling duration |
| PTPN11 | Protein tyrosine phosphatase SHP-2, modulates signaling | Mutations linked to leukemia |
| IL3 | Ligand for the receptor complex | Cytokine that activates the receptor |
| CSF2 | GM-CSF, shares beta subunit | Cross-talk with IL-3 signaling |
| IL5 | IL-5, shares beta subunit | Cross-talk with IL-3 signaling |
| CD34 | Hematopoietic progenitor marker | Used to identify IL-3-responsive cells |
| KIT | Stem cell factor receptor, cooperates with IL-3R | Synergistic signaling in progenitors |
How Is interleukin-3 receptor complex Regulated?
The interleukin-3 receptor complex is regulated at multiple levels. Expression of the alpha subunit (IL3RA/CD123) is controlled by lineage-specific transcription factors and can be upregulated in leukemia. The beta subunit (CSF2RB/CD131) is constitutively expressed in many hematopoietic cells. Signaling is negatively regulated by SOCS proteins and phosphatases that attenuate JAK/STAT activation. Additionally, receptor internalization and degradation modulate the duration of signaling. In inflammatory conditions, cytokines such as TNF-alpha and IFN-gamma can influence receptor expression.
interleukin-3 receptor complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL3RA | Acute myeloid leukemia; CD123 overexpression | CRISPR knockout or knock-in of CD123 epitope in AML cell lines |
| CSF2RB | Myeloproliferative disorders; shared beta signaling | Point mutation of JAK binding sites in CSF2RB |
| JAK2 | Myeloproliferative neoplasms | Knock-in of JAK2 V617F mutation in hematopoietic cells |
| STAT5A/B | Leukemia; survival signaling | Knockout of STAT5A/B in AML cell lines |
| SOCS1 | Inflammatory diseases; negative regulation | Overexpression of SOCS1 to dampen IL-3 signaling |
Acute Myeloid Leukemia (AML)
CD123 (IL3RA) is overexpressed in a large fraction of AML cases, including leukemic stem cells, making it an attractive therapeutic target. Antibody-drug conjugates, bispecific T-cell engagers, and CAR-T cells targeting CD123 are in clinical development. However, CD123 is also expressed on normal hematopoietic progenitors, raising concerns about myelotoxicity; epitope prime editing has been proposed to shield hematopoietic cells from CD123 immunotherapy.
Myeloproliferative Neoplasms and Inflammatory Diseases
Dysregulated IL-3 receptor signaling can contribute to myeloproliferative disorders and inflammatory conditions. Mutations in JAK2 or other signaling components can lead to cytokine-independent growth. In gout, innate immune responses involving cytokines may intersect with IL-3 signaling, though direct evidence is limited.
Allergic and Eosinophilic Disorders
Because the beta subunit is shared with the IL-5 receptor, which is critical for eosinophil biology, targeting the common beta chain could affect IL-3 signaling and has implications for asthma and eosinophilic diseases. However, selective targeting of the alpha subunit may spare IL-5 and GM-CSF functions.
From interleukin-3 receptor complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IL3RA knockout abolish IL-3 response? | CRISPR knockout of IL3RA in hematopoietic cell lines |
| How does a point mutation in CSF2RB affect JAK2 binding? | Point mutation knock-in of CSF2RB in Ba/F3 cells |
| Can a tagged IL3RA be used to track receptor trafficking? | Knock-in of fluorescent tag at IL3RA locus |
| Does overexpression of CD123 enhance leukemic growth? | Overexpression of IL3RA in AML cell lines |
| What is the effect of JAK2 V617F on IL-3 independence? | Knock-in of JAK2 V617F in primary hematopoietic cells |
| Can epitope editing protect cells from CD123 CAR-T? | Prime editing of CD123 epitope in HSPCs |
How to Study the interleukin-3 receptor complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Surface expression of CD123 and CD131 | Phenotyping of hematopoietic cells |
| Western blot | Protein levels and phosphorylation status | Validation of signaling activation |
| Co-immunoprecipitation | Physical interaction between subunits | Assessment of receptor assembly |
| CRISPR knockout | Loss-of-function effects | Determining subunit requirement |
| CRISPR knock-in | Tagged or mutated receptor | Tracking and functional domain mapping |
| Cryo-EM | 3D structure of receptor complex | Understanding assembly and ligand binding |
| RNA-seq | Transcriptional changes upon receptor activation | Identifying downstream targets |
| Phospho-proteomics | Global signaling changes | Mapping pathways activated by IL-3 |
Flow Cytometry and Immunophenotyping
Flow cytometry is widely used to detect surface expression of CD123 (IL3RA) and CD131 (CSF2RB) on hematopoietic cells. This method allows quantification of receptor levels and sorting of receptor-positive populations for downstream assays.
Western Blotting and Immunoprecipitation
Western blotting and co-immunoprecipitation can assess the assembly of the alpha and beta subunits and the activation of downstream signaling molecules such as phospho-STAT5. These techniques are essential for validating receptor complex formation and signaling competence.
CRISPR-Cas9 Genome Editing
CRISPR-Cas9 knockout of IL3RA or CSF2RB is used to determine the requirement for each subunit in IL-3 signaling. Point mutations and knock-in of tags or epitope edits enable fine mapping of functional domains and the development of immunotherapy-resistant cells.
Structural Biology (Cryo-EM)
Cryo-electron microscopy has been used to solve the structure of the related IL-5 receptor complex, providing insights into the assembly of common beta cytokine receptors. Similar approaches can be applied to the IL-3 receptor complex to understand ligand binding and subunit interactions.
How CRISPR Can Be Used to Study GO:0005894 interleukin-3 receptor complex
Knockout
CRISPR knockout of IL3RA or CSF2RB can completely abolish IL-3 receptor function, allowing researchers to test the requirement for each subunit in survival, proliferation, and differentiation assays. Knockout cell lines are also useful for reconstitution experiments with wild-type or mutant receptors.
Point Mutation
Point mutations can be introduced into IL3RA or CSF2RB to dissect specific residues involved in ligand binding, subunit interaction, or JAK kinase recruitment. For example, mutating the JAK-binding box in CSF2RB can prevent signal transduction while preserving receptor assembly.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) or epitope tags into the endogenous IL3RA locus enables real-time tracking of receptor expression and trafficking. Knock-in of disease-associated mutations, such as JAK2 V617F, can model myeloproliferative neoplasms.
Overexpression
Overexpression of IL3RA (CD123) in hematopoietic cell lines can mimic the elevated receptor levels seen in AML and test whether increased receptor expression enhances IL-3 responsiveness or leukemic growth. Overexpression of SOCS1 can be used to study negative regulation.
How EDITGENE Supports interleukin-3 receptor complex Research
Researchers studying interleukin-3 receptor complex-related genes often need to determine whether a candidate gene is causally involved in receptor assembly, signaling, or disease. EDITGENE provides a comprehensive suite of CRISPR services to enable precise genetic manipulation and functional interrogation of the IL-3 receptor complex and its components.
Contact EDITGENE today to design your custom CRISPR model for interleukin-3 receptor complex research.
Frequently Asked Questions About interleukin-3 receptor complex
What is the interleukin-3 receptor complex?
The interleukin-3 receptor complex (GO:0005894) is a cell-surface protein complex that binds interleukin-3. It consists of an alpha subunit (IL3RA/CD123) specific for IL-3 and a beta subunit (CSF2RB/CD131) shared with GM-CSF and IL-5 receptors.
What genes are involved in the interleukin-3 receptor complex?
The core genes are IL3RA (alpha subunit) and CSF2RB (beta subunit). Signaling involves JAK2, STAT5A, STAT5B, and other downstream molecules.
What is the function of CD123 in the IL-3 receptor?
CD123 is the alpha subunit that binds IL-3 with high affinity and confers ligand specificity. It is overexpressed in AML and is a target for immunotherapy.
How is the interleukin-3 receptor complex structured?
It is a heterodimer of an alpha chain (CD123) and a beta chain (CD131). The beta chain is shared with GM-CSF and IL-5 receptors and contains the signaling domains.
What diseases are associated with the interleukin-3 receptor complex?
Dysregulation is linked to acute myeloid leukemia, myeloproliferative neoplasms, and inflammatory conditions. CD123 overexpression is a hallmark of AML.
How can CRISPR be used to study the IL-3 receptor complex?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to dissect the roles of IL3RA, CSF2RB, and downstream signaling components.
What is the shared beta subunit (CD131)?
CD131 is the common beta subunit for IL-3, GM-CSF, and IL-5 receptors. It is essential for signal transduction and explains overlapping cytokine functions.
Why is the IL-3 receptor a target for cancer therapy?
CD123 is overexpressed on leukemic stem cells, making it an attractive target for antibody-drug conjugates, bispecific antibodies, and CAR-T cells.
What signaling pathways are activated by the IL-3 receptor?
JAK/STAT, PI3K/AKT, and MAPK pathways are activated, promoting survival, proliferation, and differentiation.
How is IL-3 receptor expression regulated?
Expression is controlled by lineage-specific transcription factors and can be upregulated in leukemia. Negative feedback is mediated by SOCS proteins and phosphatases.
Conclusion
The interleukin-3 receptor complex (GO:0005894) is a critical cytokine receptor that regulates hematopoietic cell survival, proliferation, and differentiation. Its unique alpha subunit (CD123) and shared beta subunit (CD131) make it a paradigm for understanding cytokine receptor cross-talk and a prime target for therapeutic intervention in leukemia and inflammatory diseases. Continued research using advanced CRISPR models and structural biology will further illuminate its biology and unlock new treatment strategies.
References
- 1. Caveney NA et al.. 2024. Structure of the interleukin-5 receptor complex exemplifies the organizing principle of common beta cytokine signaling.. Mol Cell 84(10):1995-2005.e7 PMID: 38614096
- 3. de Lima JD et al.. 2023. Genetic and Epigenetic Regulation of the Innate Immune Response to Gout.. Immunol Invest 52(3):364-397 PMID: 36745138
- 4. Broughton SE et al.. 2014. Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody.. Cell Rep 8(2):410-9 PMID: 25043189
- 5. Inaba T. 2004. Cytokine-mediated cell survival.. Int J Hematol 80(3):210-4 PMID: 15540894
- 6. Smith BR. 1990. Regulation of hematopoiesis.. Yale J Biol Med 63(5):371-80 PMID: 2293498
- 7. Hara T et al.. 1996. Function and signal transduction mediated by the interleukin 3 receptor system in hematopoiesis.. Stem Cells 14(6):605-18 PMID: 8948019
- 8. Ji RJ et al.. 2024. Epitope prime editing shields hematopoietic cells from CD123 immunotherapy for acute myeloid leukemia.. Cell Stem Cell 31(11):1650-1666.e8 PMID: 39353428
